Boston Scientific enhances its patent portfolio with BTG acquisition

An in-depth analysis shows that the American medical device manufacturer may not gain much in terms of quantity from its $4 billion purchase, but that the British healthcare company’s IP assets will boost its peripheral interventional offerings

Get unlimited access to all IAM content